Royalty Pharma plc
RPRX
Rang in Aktien
#885
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Aktienkurs
$60.64
Marktkapitalisierung
$27.00B
Veränderung (1 Tag)
-0.52%
Veränderung (1 Jahr)
63.86%
Land
US
Handel Royalty Pharma plc (RPRX)
Kategorie
Healthcare
EPS für Royalty Pharma plc (RPRX)
EPS zum June 2026 TTM: $2.41
Laut den aktuellen Finanzberichten und dem Aktienkurs von Royalty Pharma plc beträgt das aktuelle EPS des Unternehmens (TTM) $2.41. Am Ende des Jahres 2024 betrug das EPS $1.92 ein Rückgang im Vergleich zu dem EPS von 2023, das $2.54 betrug.
EPS-Verlauf von Royalty Pharma plc von 2015 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $2.41 | 34.64% |
| 2025 | $1.79 | -6.61% |
| 2024 | $1.92 | -24.41% |
| 2023 | $2.54 | 2,492.43% |
| 2022 | $0.10 | -93.45% |
| 2021 | $1.49 | -42.47% |
| 2020 | $2.60 | -59.54% |
| 2019 | $6.42 | 182.80% |
| 2018 | $2.27 | 13.86% |
| 2017 | $1.99 | 113.83% |
| 2016 | $0.93 | -2.67% |
| 2015 | $0.96 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.52 | -78.42% |
US
|
|
| $0.02 | -99.22% |
HK
|
